ARYx Therapeutics (ARYx Therapeutics) GF Value : $0.00 (As of May. 05, 2024)

View and export this data going back to 2007. Start your Free Trial

What is ARYx Therapeutics GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-05), ARYx Therapeutics's share price is $0.0005. ARYx Therapeutics's GF Value is $0.00. Therefore, ARYx Therapeutics's Price-to-GF-Value for today is .

Based on the relationship between the current stock price and the GF Value, GuruFocus believes ARYx Therapeutics is Not Valued.

ARYx Therapeutics (OTCPK:ARYX) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

ARYx Therapeutics's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0005	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ARYx Therapeutics GF Value Related Terms

Thank you for viewing the detailed overview of ARYx Therapeutics's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

ARYx Therapeutics (ARYx Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ARYx Therapeutics Inc (OTCPK:ARYX) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

6300 Dumbarton Circle, Fremont, CA, USA, 94555

Website

http://www.aryx.com

ARYx Therapeutics Inc is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs.

Executives

Newhall Charles W Iii	10 percent owner	1119 ST PAUL ST, BALTIMORE MD 21202
C Richard Kramlich	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ryan D Drant	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Krishna Kittu Kolluri	10 percent owner
New Enterprise Associates 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea Partners 12, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 12 Gp, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Mark W Perry	10 percent owner
Patrick J Kerins	10 percent owner
Forest Baskett	10 percent owner
Growth Equity Opportunities Fund, Llc	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Peter J Barris	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
M James Barrett	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Scott D Sandell	10 percent owner
Nicholas Galakatos	10 percent owner	THE JOHN HANCOCK TOWER, 200 CLARENDON STREET, 54TH FLOOR, BOSTON MA 02116

ARYx Therapeutics (ARYx Therapeutics) Headlines

No Headlines